Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GSK2830371 |
| Synonyms | |
| Therapy Description |
GSK2830371 is an allosteric, small molecule inhibitor of PPM1D, which results in increased phosphorylation Ppm1d substrates and may result in tumor growth inhibition (PMID: 24390428, PMID: 31136458). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GSK2830371 | GSK-2830371 | PPM1D Inhibitor 3 | GSK2830371 is an allosteric, small molecule inhibitor of PPM1D, which results in increased phosphorylation Ppm1d substrates and may result in tumor growth inhibition (PMID: 24390428, PMID: 31136458). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 wild-type | neuroblastoma | predicted - sensitive | GSK2830371 | Preclinical | Actionable | In a preclinical study, GSK2830371 inhibited proliferation of neuroblastoma cell lines carrying wild-type TP53 in culture (PMID: 25658463). | 25658463 |
| TP53 mutant | neuroblastoma | resistant | GSK2830371 | Preclinical | Actionable | In a preclinical study, neuroblastoma cell lines harboring TP53 mutations were resistant to GSK2830371 induced growth inhibition in culture (PMID: 25658463). | 25658463 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|